StockData
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc (XFOR) stock

XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30
$2.83−0.29 (-9.29%)

Close on Nov 16, 2026Market cap $280.59MP/E –Yield –

X4 Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

X4 Pharmaceuticals's total assets was $231.82M at Sep 30, 2026. For fiscal 2025 it was $290.46M, up 98.3% from the year before. The highest annual figure on record is $290.46M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$290.46M+98.3%
FY2024Dec 31, 2024$146.45M-0.6%
FY2023Dec 31, 2023$147.26M-5.4%
FY2022Dec 31, 2022$155.59M+32.8%
FY2021Dec 31, 2021$117.18M-4.6%
FY2020Dec 31, 2020$122.87M-23.5%
FY2019Dec 31, 2019$160.70M+1516.0%
FY2018Dec 31, 2018$9.94M-87.8%
FY2017Dec 31, 2017$81.25M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$231.82M+41.7%
Q2 FY2026Jun 30, 2026$253.06M+140.6%
Q1 FY2026Mar 31, 2026$270.28M+107.9%
Q4 FY2025Dec 31, 2025$290.46M+98.3%
Q3 FY2025Sep 30, 2025$163.56M-8.2%
Q2 FY2025Jun 30, 2025$105.17M-50.1%
Q1 FY2025Mar 31, 2025$130.01M+15.9%
Q4 FY2024Dec 31, 2024$146.45M-0.6%
Q3 FY2024Sep 30, 2024$178.17M+2.7%
Q2 FY2024Jun 30, 2024$210.61M+69.3%
Q1 FY2024Mar 31, 2024$112.18M-27.9%
Q4 FY2023Dec 31, 2023$147.26M+29.9%
Q2 FY2023Jun 30, 2023$173.40M+114.0%
Q1 FY2023Mar 31, 2023$124.41M+24.9%
Q4 FY2022Dec 31, 2022$155.59M+32.8%
Q3 FY2022Sep 30, 2022$113.41M-5.9%
Q2 FY2022Jun 30, 2022$81.02M-42.8%
Q1 FY2022Mar 31, 2022$99.63M-38.1%
Q4 FY2021Dec 31, 2021$117.18M-4.6%
Q3 FY2021Sep 30, 2021$120.52M-9.5%
Q2 FY2021Jun 30, 2021$141.66M-0.6%
Q1 FY2021Mar 31, 2021$161.04M+4.8%
Q4 FY2020Dec 31, 2020$122.87M-23.5%
Q3 FY2020Sep 30, 2020$133.13M+21.5%
Q2 FY2020Jun 30, 2020$142.53M+6.8%
Q1 FY2020Mar 31, 2020$153.72M+145.8%
Q4 FY2019Dec 31, 2019$160.70M+1516.0%
Q3 FY2019Sep 30, 2019$109.54M+138.6%
Q2 FY2019Jun 30, 2019$133.51M+133.4%
Q1 FY2019Mar 31, 2019$62.55M-9.6%
Q4 FY2018Dec 31, 2018$9.94M-87.8%
Q3 FY2018Sep 30, 2018$45.90M–
Q2 FY2018Jun 30, 2018$57.21M–
Q1 FY2018Mar 31, 2018$69.22M–
Q4 FY2017Dec 31, 2017$81.25M–

More X4 Pharmaceuticals figures

See a number that looks wrong?